These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6139164)

  • 1. Vulnerability to extrapyramidal side effects.
    Van Putten T
    Clin Neuropharmacol; 1983; 6 Suppl 1():S27-34. PubMed ID: 6139164
    [No Abstract]   [Full Text] [Related]  

  • 2. Tardive dyskinesia circa 2006.
    Kane JM
    Am J Psychiatry; 2006 Aug; 163(8):1316-8. PubMed ID: 16877639
    [No Abstract]   [Full Text] [Related]  

  • 3. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic discontinuation and tardive dyskinesia risk.
    Sherr JD; Medoff D; Thaker G
    Am J Psychiatry; 1999 Jul; 156(7):1125-6. PubMed ID: 10401483
    [No Abstract]   [Full Text] [Related]  

  • 5. Decreased extrapyramidal side effects and polypsichopharmacy in family practice outpatients.
    Holt RJ
    Bol Asoc Med P R; 1983 Aug; 75(8):351-2. PubMed ID: 6139115
    [No Abstract]   [Full Text] [Related]  

  • 6. Extrapyramidal side effects of antipsychotic medications.
    Harris E
    Am J Nurs; 1981 Jul; 81(7):1324-8. PubMed ID: 6113762
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluoxetine and extrapyramidal side effects.
    Fishbain DA
    Am J Psychiatry; 1996 Mar; 153(3):449. PubMed ID: 8610852
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    Am J Psychiatry; 2006 Aug; 163(8):1438-40. PubMed ID: 16877660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
    Gharabawi GM; Bossie CA; Zhu Y
    Am J Psychiatry; 2006 May; 163(5):938-9. PubMed ID: 16648343
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorting through EPS (extrapyramidal symptoms).
    Blair DT
    Geriatr Nurs; 1991; 12(5):244-6. PubMed ID: 1687319
    [No Abstract]   [Full Text] [Related]  

  • 12. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models.
    Casey DE
    Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821
    [No Abstract]   [Full Text] [Related]  

  • 13. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.
    Marsden CD; Jenner P
    Psychol Med; 1980 Feb; 10(1):55-72. PubMed ID: 6104342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapyramidal reactions. Neuropsychiatric mimics in patients with AIDS.
    Swenson JR; Erman M; Labelle J; Dimsdale JE
    Gen Hosp Psychiatry; 1989 Jul; 11(4):248-53. PubMed ID: 2568309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():15-20. PubMed ID: 10739326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Iatrogenic extrapyramidal disorders].
    Ludin HP
    Schweiz Med Wochenschr; 1990 Jun; 120(23):855-8. PubMed ID: 1972812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.
    McClelland HA
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):401-3. PubMed ID: 9966
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium and extrapyramidal side effects.
    El-Defrawi MH
    Am J Psychiatry; 1982 Aug; 139(8):1079. PubMed ID: 6124137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.